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Abstract
Rationale: Down syndrome (DS) is the most common chromosome disorder in live born infants, affecting several body systems,
but usually sparing skeletal muscles. We present the case of a child with coexistence of DS and dystrophinopathy. Only 1 similar case
has been reported so far.
Patient Concerns: An 8-year-old boy with DS had a history of incidental ﬁnding of increased serum creatine kinase levels up to
1775U/L (normal values 38–174U/L). He presented no delay in motor development; at the neurological examination, no muscle
weakness or fatigability was detected in 2 different evaluations performed over a 6-month period.
Diagnoses: Skeletal muscle biopsy revealed marked dystrophic changes with patchy immunostaining for dystrophin. The
Duchenne muscular dystrophy gene was screened for deletions by multiplex polymerase chain reaction, but no mutations were
found. Sequence analysis of the Duchenne muscular dystrophy gene revealed a splice-site mutation c.1812+1G>A in intron 15 and
conﬁrmed a diagnosis of Becker muscular dystrophy.
Interventions:The patient has started a speciﬁc physiotherapy that avoided any deterioration in motor development andmuscular
wasting.
Outcomes: A multidisciplinary follow-up was initiated. The genetician that followed the patient for DS was supported by the
neurologist, the physiotherapist, the pulmonologist, and the cardiologist.
Lessons: This peculiar “double trouble” case exempliﬁes the value of careful clinical evaluation and adequate clinical experience to
identify the concomitance of 2 different genetic syndromes in the same patient, and it points out the signiﬁcance of muscular strength
assessment in DS patients to make the most correct prognosis, and, consequently, to organize the best long-term care.
Abbreviations: BMD = Becker muscular dystrophy, CK = creatine kinase, DMD = Duchenne muscular dystrophy, DS = Down
syndrome.
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1. Introduction 1000 babies born each year.[1] It is caused by triplicate stateDown syndrome (DS, OMIM #190685) is 1 of the most common
chromosome abnormalities in humans, occurring in about 1 perEditor: Catherine Clelland.
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1(trisomy) of all or of a critical portion of chromosome 21, usually
by nondisjunction.[2] It is characterized mainly by peculiar facial
features, physical growth delay, mild to moderate intellectual
disability, high rate of congenital heart defects and hypothyroid-
ism, high risk for leukemia and lower, but signiﬁcant rates of
gastrointestinal malformations, which often require surgery
within the ﬁrst days to weeks of life.[3] Other surgical conditions
that occur at higher rates include Hirschsprung disease,
polydactyly, cleft palate, and cataracts.
Mutations in Duchenne muscular dystrophy (DMD) gene,
which encodes the protein dystrophin and is located on
chromosome X,[4] cause a spectrum of muscle diseases affecting
male individuals and named dystrophinopathies. Two main
forms are recognized, namely Duchenne and Becker muscular
dystrophies (DMD and BMD, OMIM #310200 and #300376,
respectively). DMD is the most common form of inherited muscle
disease in childhood, with an estimated incidence of 1 in 3500
born males.[5] It presents in early childhood and it is rapidly
progressive, with affected children being wheelchair-bound by 12
years of age. BMD is a generally milder andmore variable form of
dystrophinopathy, with an incidence of 1 in 18,518 male
births.[5] Indeed, BMD phenotype can range from asymptomatic
individuals with increased serum creatine kinase (CK) levels and
muscle cramps, to more invalidating forms with severe muscle
weakness and/or dilated cardiomyopathy. BMD patients usually
remain ambulatory into their 20s.[6] The Duchenne phenotype is
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of the mRNA transcript, leading to a truncated gene product.[7,8]
In BMD, the mutation does not affect the reading frame; rather
it results in the synthesis of shorter, but partly functional
dystrophin molecules.[7,8]
We describe a peculiar case presenting a combination of
chromosome 21 trisomy and in-frame DMD gene deletion. The
patient has typical features of both DS and BMD.2. Case
2.1. Presenting concerns
An 8-year-old boy with DS had been referred to us by an
attentive neurologist for recurrent ﬁndings of increased serum
CK levels. The patient was found to have an incidental
elevation of serum transaminases that had led to a gastroenter-
ological evaluation at around 6 years of age. During the same
year, he was found to have elevated serum CK levels, up to
1775U/L (normal values 38–174U/L), conﬁrmed in several
serial assessments. Family history was negative for inherited
diseases.
2.2. Clinical ﬁndings
Medical history was negative for delay inmotor development and
he did not show progressive muscular wasting. At the
neurological examination, he showed characteristic DS facial
features, but no muscle weakness or fatigability were detected in
2 different evaluations performed over a 6-month period.
2.3. Diagnostic focus and assessment
Electromyography ﬁndings revealed immediately a myopathic
pattern. Because of the peculiarity and complexity of the clinical
presentation, after the approval of the Ethics Committee of
Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoFigure 1. Skeletal muscle biopsy. Gomori trichrome (A, B) and H&E (C) stainin
description). Immunohistochemistry of dystrophin: DYS-1 (rod domain) (D) and DYS
sarcolemmal immunostaining and a few dystrophin negative ﬁbers.
2and upon parental signature of written informed consent, the
child underwent a biceps brachial skeletal muscle biopsy that
showed moderate dystrophic alterations consisting of scattered
rounded opaque ﬁbers, rare necrotic ﬁbers undergoing phagocy-
tosis, and basophilic muscle ﬁbers. Immunocytochemical
studies of dystrophin using DYS-1 (rod domain) and DYS-2
(C-terminus) monoclonal antibodies demonstrated normal
immunoreactivity. DYS-3 (N-terminus) antibody showed weak
immunostaining at the sarcolemma and a few dystrophin-
negative ﬁbers. Normal sarcolemmal immunostaining was
observed with the antibodies against caveolin, and a and
g-sarcoglycan.
DNA analyses for DMD/BMD were performed after written
informed consent. The DMD gene was screened for deletions by
multiplex polymerase chain reaction, but no mutations were
found. Sequence analysis of the DMD gene revealed a splice-site
mutation c.1812+1G>A in intron15.Themutation results in exon
15 skipping, a change that would leave the reading frame intact.2.4. Therapeutic focus and assessment
The patient has started a speciﬁc physiotherapy that avoided any
deterioration in motor development and muscular wasting. No
other medical or surgical therapies were required.2.5. Follow-up and outcomes
As soon as the diagnosis was performed, a multidisciplinary
follow-up was initiated. The genetician that followed the patient
for DS was supported by the neurologist, the physiotherapist, the
pulmonologist, and the cardiologist.2.6. Timeline
Figure 1 represents the skeletal muscle biopsy that permitted the
diagnosis.g showed typical histologic changes of muscular dystrophy (see the txt for
-2 (C-terminus) (E) were normal; DYS-3 (F) (N-terminus) antibody showed weak
[12]
Figure 3. Molecular genetic analysis of the mRNA DMD gene. Base change c.1812+1G>A leads to a splice site mutation in intron 15, resulting in exon 15 deletion.
DMD=Duchenne muscular dystrophy.
Figure 2. Molecular genetic analysis of the cDNA DMD gene. BMD exon/intron 15, base change c,1812+1G>A. BMD=Becker muscular dystrophy, DMD=
Duchenne muscular dystrophy.
Lerario et al. Medicine (2016) 95:49 www.md-journal.comAs soon as the results of the skeletal muscle biopsy were
available, molecular genetic analysis was performed and
documented a splice-site mutation c.1812+1G>A in intron 15.
Figure 2 shows the molecular genetic analysis of the cDNADMD
gene, whereas Fig. 3 reports molecular genetic analysis of the
mRNA DMD gene.
3. Discussion
We report the case of a 8-year-old boy with coinheritance of DS
and BMD. An increase in CK serum levels is not a typical feature
of DS, although a signiﬁcant increase in CK values is reported in
obese DS patients compared with nonobese ones.[9] Our patient,
who had both high serum CK levels and a myopathic
electromyography pattern, underwent skeletal muscular biopsy,
which revealed a weak Dys 3 immunostain compatible with a
diagnosis of BMD. The diagnosis was conﬁrmed by DMD gene
analysis, which revealed an intronic splice-site mutation causing
exon 15 skipping and keeping the reading frame intact. The
typical BMD great phenotype variability[10] may account for the
normal muscular strength in the patient.
In DS patients, considerable evidence underlines the common
presence of reduced muscle strength, only partially explained by
degree of intellectual disability.[3] Also, Cowley et al[11] showed
lower expression of cytochrome-c oxidase in Soleus muscles of
DS murine model, Ts65Dn, our patient, however, has normal
COX activity. Despite these data, neuromuscular anomalies
are very uncommon in DS, although DS has been previously3described in 2 independent patients affected by DMD and
BMD,[13] respectively.
The concomitant presence of DS and BMD in a single patient is
logically assumed to be coincidental. The incidence of DS is 1 per
1000 birth,[1] and the frequency of BMD is estimated to be 1
in 18,518 male births.[5] However, the possibility of being
affected with 2 relatively common inherited genetic conditions,
although rare, should be consideredwhen ﬁndings are incoherent
with the primary diagnosis. Although the genetic etiology is
different, dystrophinopathies have been reported in males
with chromosomal abnormalities, more speciﬁcally DMD in
Turner and Klinefelter syndrome,[14–16] and BMD in Noonan
syndrome.[17]
The rarity of this disease association underlines the value of
adequate clinical experience; even more, it emphasizes how a
multidisciplinary approach is essential in managing and treating
these patients. Because reduction in muscle strength interferes
with everyday activities and limits opportunities for indepen-
dent living, it is extremely important to assess DS patients’
muscle strength and to detect any genetic comorbidities to make
the most correct prognosis and, consequently, organize the best
long-term care.4. Patient’s and parents’ perspective
We were happy to identify the cause of the increase in CK in our
child and we are conﬁdent in the multidisciplinary follow-up that
has been started.
[7] Tuffery-Giraud S, Béroud C, Leturcq F, et al. Genotype-phenotype
Lerario et al. Medicine (2016) 95:49 Medicine5. Informed consent
The patient’s parents provided their written informed consent for
the publication of this study.
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